Caregiver-Assisted Oral Fluid-based HIV Screening in Children: Uganda

Sponsor
Catholic Relief Services (Other)
Overall Status
Completed
CT.gov ID
NCT04774666
Collaborator
Centers for Disease Control and Prevention (U.S. Fed)
4,865
32
5.7
152
26.9

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the acceptability, feasibility and effectiveness of a caregiver-assisted oral fluid-based HIV test to screen children for HIV. The results of this study are intended to support expanded access to HIV testing and treatment services for children, and to ensure that all newly diagnosed children are linked to clinical care.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Acceptability of OraQuick Advance© Rapid HIV-1/2 Antibody screening

Detailed Description

Rationale: Globally, there are 1.8 million children living with HIV (CLHIV), however, despite great progress over the past 15 years, only 52% are receiving antiretroviral therapy (ART), leaving approximately 864,000 children in need of treatment.1 Pediatric case finding is the first, critical step to close the pediatric ART gap. In Uganda, there are an estimated 36,873 CLHIV in need of HIV treatment.2 Reaching this population is challenging, because children are dependent on parents and caregivers to access HIV testing services. Parents and caregivers often face logistical, societal and other barriers that limit the uptake of testing services for children. In order to achieve the second and third UNAIDS 95 targets for pediatric HIV treatment coverage and viral load suppression to reach epidemic control, country programs need to utilize increasingly targeted and innovative testing modalities to optimize the identification CLHIV. Oral fluid-based screening may present a safe, convenient and reliable way to identify CLHIV that can expand access to essential testing services in resource-limited settings where most CLHIV reside.

Methods: The study will use a cross-sectional cluster sampling design, in which 32 facilities in 16 districts will be selected using probability-proportional-to-size (PPS) sampling. In the 32 selected facilities, index parent/caregivers of approximately 4,687 children will be recruited to accept test kits for their children. Adult index parent/caregivers will be consented to participate in the study and asked for parental permission for their child(ren) to participate, given a number of oral screening kits corresponding to the number of children eligible for screening, and followed-up to confirm the oral fluid-based screening results and participate in a testing experience survey. Any children who screen HIV reactive will receive confirmatory testing and active linkage to care and treatment services. A cost analysis which includes savings associated with facility or home-based costs averted, using existing sources to estimate the costs of facility-based testing and home-based by a community health worker (CHW), preferably from antenatal settings will be undertaken.

Study Design

Study Type:
Observational
Actual Enrollment :
4865 participants
Observational Model:
Ecologic or Community
Time Perspective:
Cross-Sectional
Official Title:
Caregiver-Assisted Oral Fluid-based HIV Screening in Children: Estimation of Acceptability, Feasibility and Effectiveness Linked to Index Testing Services in Uganda
Actual Study Start Date :
Apr 19, 2021
Actual Primary Completion Date :
Oct 8, 2021
Actual Study Completion Date :
Oct 8, 2021

Outcome Measures

Primary Outcome Measures

  1. Estimate the acceptability of implementing caregiver-assisted oral fluid-based HIV screening of children as part of index testing services for HIV-positive adults. [6 months]

    Proportion of eligible index parent/caregivers (disaggregated by sex) that accepted an oral fluid-based HIV screening kit as part of innovative index testing services for their eligible children when first offered. Proportion of eligible index parent/caregivers (disaggregated by sex) that accepted an oral fluid-based HIV screening kit as part of innovative index testing services for their eligible children when they returned for a subsequent visit. Proportion of eligible children (i.e. unknown HIV status) screened with an oral fluid-based HIV screening kit.

  2. Estimate the feasibility of implementing caregiver-assisted oral fluid-based HIV screening for children as part of index testing services for HIV-positive adults. [6 months]

    Proportion of index parent/caregivers who reported that the caregiver-assisted oral fluid-based HIV screening kit to screen children for HIV was easy to use. Proportion of index parent/caregivers who reported needing additional assistance with administering the oral fluid-based HIV screening kit. Proportion of index parent/caregivers who reported adverse events related to the use of caregiver-assisted oral fluid-based HIV screening kits to screen their children for HIV.

  3. Estimate the effectiveness of caregiver-assisted oral fluid-based HIV screening on testing yield, return to clinic, and linkage to ART for newly identified CLHIV. [6 months]

    Proportion of eligible children screened reactive through a caregiver-assisted oral fluid-based HIV screening kit (i.e., yield). Proportion of eligible children who screened reactive through a caregiver-assisted oral fluid-based HIV screening kit who received confirmatory testing, within 1 day, 1 week, 1 month of their reactive screen. Proportion of eligible children who screened reactive through a caregiver-assisted oral fluid-based HIV screening kit who were started on ART within 1 day, 1 week, 1 month of their confirmatory test. Proportion of index parent/caregivers who were offered an oral fluid-based test kit to screen their eligible children for HIV used it.

Secondary Outcome Measures

  1. Estimate the cost of caregiver-assisted oral fluid-based HIV screening compared to the standard cost of the existing referral to testing program, from the perspective of the health care provider. [6 months]

    Comparative costs between oral fluid-based screening and the costs of the existing referral to testing program, from the perspective of the health care provider.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria for Index parent/caregivers:
  • HIV-positive diagnosis

  • 18 years old or older

  • Emancipated minors (15-17 years of age) with eligible children

Inclusion Criteria for eligible children:
  • Biological children (of an index parent/caregiver) 18 months - 14 years of age with an unknown HIV status

  • Non-biological children living in the same household as the index parent/caregivers where the child has a history of HIV exposure (where the mother is HIV-positive, of unknown status, unavailable for testing, or who is deceased)

  • Biological children (of an index parent/caregiver) 18 months - 14 years of age, as well as non-biological children living in the same household as the index parent/caregiver where the child has a history of HIV exposure (where the mother is HIV-positive, of unknown status, unavailable for testing, or who is deceased), with a known previous HIV-negative status completed less than three months following the cessation of breastfeeding and whose parent/caregiver states that there is reason to suspect a new exposure

Inclusion criteria for participation in survey after completion of care giver-assisted oral fluid-based HIV screening:

• Adult index parents who complete the oral-based HIV screening with at least one eligible child, regardless of screening result.

Exclusion Criteria for Index parent/caregivers:
  • Adults answering "yes" to any of the first three intimate partner violence (IPV) risk assessment questions

  • Adults answering "yes", "maybe" or I don't know" to the fourth IPV question

  • Those unable to provide independent informed consent due to mental disability or other limitations (as deemed by study staff)

Exclusion Criteria for eligible children:
  • Children <18 months of age

  • Children 18 months - 14 years of age with a known HIV-positive status

  • Biological children (of an index parent/caregiver) 18 months - 14 years of age where the child has a history of HIV exposure (where the mother is HIV-positive, of unknown status, unavailable for testing, or who is deceased), with previous known HIV-negative status completed less than three months following the cessation of breastfeeding and whose parent/caregiver states that they have no reason to suspect a new exposure

  • Non-biological children living in the same household as the index parent/caregiver age where the child has a history of HIV exposure (where the mother is HIV-positive, of unknown status, unavailable for testing, or who is deceased), with previous known HIV-negative status completed less than three months following the cessation of breastfeeding and whose parent/caregiver states that they have no reason to suspect a new exposure

  • Children still breastfeeding

  • Children with cessation of breastfeeding < 3 months

Exclusion criteria for participation in survey after completion of oral-based HIV screening:

• Adult index parent/caregivers who do not complete the oral-based HIV screening with at least one eligible child

Contacts and Locations

Locations

Site City State Country Postal Code
1 Bugiri Hospital Bugiri Bugiri District Uganda
2 Nankoma HC IV Bugiri Bugiri District Uganda
3 Kabuyanda HC IV Kabuyanda Isingiro District Uganda
4 Rwekubo HC IV Kahirimbi Isingiro District Uganda
5 Buremba HC III Kazo Kazo District Uganda
6 Kazo HC IV Kazo Kazo District Uganda
7 Butunduzi HC III Kyenjojo Kyenjojo District Uganda
8 Kigarale HC III Kyenjojo Kyenjojo District Uganda
9 Kasaali HC III Kyotera Kyotera District Uganda
10 Barr HC III Lira Lira District Uganda
11 Lira Regional Ref Hospital Lira Lira District Uganda
12 Luwero HC IV Kampala Luwero District Uganda
13 St. Luke Namaliga HC III Kampala Luwero District Uganda
14 Kinoni HC III Bukoto Lwengo District Uganda
15 Kiwangala HC III Mbirizi Lwengo District Uganda
16 Kiyumba HC IV Bukoto Masaka District Uganda
17 Buwunga HC III Masaka Masaka District Uganda
18 Mbarara Regional Ref Hospital Mbarara Mbarara District Uganda
19 Nyamityobora HC II Mbarara Mbarara District Uganda
20 Kyantungo HC IV Mityana Mityana District Uganda
21 Mityana Hospital Mityana Mityana District Uganda
22 Mubende Kasambya HC III Mubende Mubende District Uganda
23 Nabingoola HC III Nabingora Mubende District Uganda
24 Mukono Cou HC IV Mukono Mukono District Uganda
25 Seeta-Nazigo HC III Nakisunga Mukono District Uganda
26 Kitwe HC IV Kitwe Ntungamo District Uganda
27 Ntungamo HC IV Ntungamo Ntungamo District Uganda
28 Lwamaggwa HC III Rakai Rakai District Uganda
29 Rakai Hospital Rakai Rakai Distsrict Uganda
30 Kajjansi HC III Busiro Wakiso District Uganda
31 Kasangati HC IV Kasangati Wakiso District Uganda
32 Mitukula HC III Kyotera Uganda

Sponsors and Collaborators

  • Catholic Relief Services
  • Centers for Disease Control and Prevention

Investigators

  • Principal Investigator: Carl C Stecker, EdD, Catholic Relief Services - USCCB

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Catholic Relief Services
ClinicalTrials.gov Identifier:
NCT04774666
Other Study ID Numbers:
  • CDC IRB 7292
First Posted:
Mar 1, 2021
Last Update Posted:
Mar 11, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 11, 2022